Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting
Abstract Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused b...
Saved in:
Published in | The Journal of infectious diseases Vol. 228; no. Supplement_7; pp. S474 - S478 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
15.11.2023
|
Subjects | |
Online Access | Get full text |
ISSN | 0022-1899 1537-6613 1537-6613 |
DOI | 10.1093/infdis/jiad354 |
Cover
Loading…
Abstract | Abstract
Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium. |
---|---|
AbstractList | Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium. Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium.Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium. Abstract Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium. |
Author | Kobinger, Gary Feldmann, Heinz Muyembe, Jean-Jacques Spiropoulou, Christina F Martins, Karen A Cross, Robert Nyhuis, Tara Woolsey, Courtney Ahuka-Mundeke, Steve Cihlar, Tomas Strong, Jim Geisbert, Thomas W Montgomery, Joel M Crozier, Ian Sprecher, Armand Marzi, Andrea Wolfe, Daniel Teicher, Carrie |
Author_xml | – sequence: 1 givenname: Armand surname: Sprecher fullname: Sprecher, Armand email: armand.sprecher@brussels.msf.org – sequence: 2 givenname: Robert surname: Cross fullname: Cross, Robert – sequence: 3 givenname: Andrea orcidid: 0000-0003-0186-9587 surname: Marzi fullname: Marzi, Andrea – sequence: 4 givenname: Karen A surname: Martins fullname: Martins, Karen A – sequence: 5 givenname: Daniel surname: Wolfe fullname: Wolfe, Daniel – sequence: 6 givenname: Joel M orcidid: 0000-0003-0523-4431 surname: Montgomery fullname: Montgomery, Joel M – sequence: 7 givenname: Christina F surname: Spiropoulou fullname: Spiropoulou, Christina F – sequence: 8 givenname: Tomas surname: Cihlar fullname: Cihlar, Tomas – sequence: 9 givenname: Steve surname: Ahuka-Mundeke fullname: Ahuka-Mundeke, Steve – sequence: 10 givenname: Tara surname: Nyhuis fullname: Nyhuis, Tara – sequence: 11 givenname: Carrie surname: Teicher fullname: Teicher, Carrie – sequence: 12 givenname: Ian surname: Crozier fullname: Crozier, Ian – sequence: 13 givenname: Jim surname: Strong fullname: Strong, Jim – sequence: 14 givenname: Gary surname: Kobinger fullname: Kobinger, Gary – sequence: 15 givenname: Courtney surname: Woolsey fullname: Woolsey, Courtney – sequence: 16 givenname: Thomas W surname: Geisbert fullname: Geisbert, Thomas W – sequence: 17 givenname: Heinz orcidid: 0000-0001-9448-8227 surname: Feldmann fullname: Feldmann, Heinz – sequence: 18 givenname: Jean-Jacques surname: Muyembe fullname: Muyembe, Jean-Jacques |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37596837$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1rFEEQxRuJmE3i1aM0eDGHTbq7er68hdXVQIJB9Dx099RILzPdY38s-N-nZdccAuKpKN7vVRX1zsiJ8w4JecPZFWcdXFs3DjZe76waoJIvyIpX0KzrmsMJWTEmxJq3XXdKzmLcMcYk1M0rcgpN1dUtNCuiHzDEBU2ye4zUO3oz7JUz1v2kG59dwjCjijkUcfSBbu3k9zbkSD_aWAT8QL_h4kOi2-Bnquh9nlJRTCrwPWIqgy7Iy1FNEV8f6zn5sf30ffNlfff18-3m5m5toGtSuVkKo2EchTRCKAY1KgRTOl0NQito66aRyPQIEkStJdO6qjhDbPWAxsA5eX-YuwT_K2NM_WyjwWlSDn2OvWgr6GQrGl7Qd8_Qnc_Blet6YJKzumMcCvX2SGU949Avwc4q_O7_fq8AVwfABB9jwPEJ4az_E09_iKc_xlMM8pnB2KSS9S4FZad_2y4PNp-X_614BLOmpjU |
CitedBy_id | crossref_primary_10_1016_S2214_109X_24_00255_9 crossref_primary_10_18699_SSMJ20240602 |
Cites_doi | 10.1093/cid/ciac732 10.3390/vaccines10111935 10.1038/s41467-021-22132-0 10.1056/NEJMoa1910993 10.1016/S2666-5247(23)00001-0 10.1038/nrd.2017.251 10.1172/jci.insight.159090 10.3390/vaccines10071004 10.1016/S0140-6736(16)32621-6 10.1093/cid/ciab215 10.1097/MS9.0000000000000596 10.1016/j.infpip.2020.100038 10.1016/S1473-3099(23)00344-4 10.3390/vaccines9030190 10.1016/j.chom.2018.12.005 10.1126/scitranslmed.aai8711 10.3390/vaccines10101582 10.1093/infdis/jiad157 |
ContentType | Journal Article |
Copyright | Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. 2023 Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. |
Copyright_xml | – notice: Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. 2023 – notice: Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
DOI | 10.1093/infdis/jiad354 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) ProQuest Nursing and Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
DocumentTitleAlternate | 10th International Symposium on Filoviruses |
EISSN | 1537-6613 |
EndPage | S478 |
ExternalDocumentID | 37596837 10_1093_infdis_jiad354 10.1093/infdis/jiad354 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | Africa |
GeographicLocations_xml | – name: Africa |
GrantInformation_xml | – fundername: NIH HHS grantid: 75N91019D00024 – fundername: NCI NIH HHS grantid: 75N91019D00024 |
GroupedDBID | --- -DZ -~X ..I .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 123 1KJ 1TH 29K 2AX 2WC 36B 3O- 4.4 41~ 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYOK ABBHK ABDFA ABDPE ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABSMQ ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACGOD ACHIC ACPQN ACPRK ACUFI ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFQV AFFZL AFHKK AFIYH AFOFC AFQQW AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJDVS AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APJGH APWMN AQDSO AQKUS AQVQM ATGXG AVNTJ AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM BZKNY C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 M49 MBLQV MHKGH MJL ML0 MVM N4W N9A NEJ NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P0- P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 VH1 W2D W8F WH7 X7H X7M Y6R YAYTL YKOAZ YXANX ZE2 ZGI ZKG ZXP ~91 AAYXX AGORE AHGBF AJBYB CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c397t-6642cb3ff24c22a036eae3c24cb5d2ba386774e0bf34326b40bb5510ee8bdecc3 |
ISSN | 0022-1899 1537-6613 |
IngestDate | Fri Jul 11 16:12:34 EDT 2025 Mon Jun 30 10:54:17 EDT 2025 Thu Apr 03 07:04:50 EDT 2025 Tue Jul 01 01:31:38 EDT 2025 Thu Apr 24 22:59:29 EDT 2025 Wed Apr 02 07:06:43 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_7 |
Keywords | therapeutics disease outbreaks clinical trials filoviruses vaccines |
Language | English |
License | This work is written by (a) US Government employee(s) and is in the public domain in the US. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c397t-6642cb3ff24c22a036eae3c24cb5d2ba386774e0bf34326b40bb5510ee8bdecc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-0186-9587 0000-0003-0523-4431 0000-0001-9448-8227 |
OpenAccessLink | https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad354/51173618/jiad354.pdf |
PMID | 37596837 |
PQID | 3041069013 |
PQPubID | 41591 |
ParticipantIDs | proquest_miscellaneous_2853948271 proquest_journals_3041069013 pubmed_primary_37596837 crossref_primary_10_1093_infdis_jiad354 crossref_citationtrail_10_1093_infdis_jiad354 oup_primary_10_1093_infdis_jiad354 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-11-15 |
PublicationDateYYYYMMDD | 2023-11-15 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Oxford |
PublicationTitle | The Journal of infectious diseases |
PublicationTitleAlternate | J Infect Dis |
PublicationYear | 2023 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Bornholdt (2023111521055128000_jiad354-B7) 2019; 25 Gilead Sciences (2023111521055128000_jiad354-B23) 2023 Wohl (2023111521055128000_jiad354-B4) 2023; 76 Cao (2023111521055128000_jiad354-B12) 2023 Henao-Restrepo (2023111521055128000_jiad354-B17) 2017; 389 Cooper (2023111521055128000_jiad354-B10) 2022; 10 Finch (2023111521055128000_jiad354-B14) 2022; 10 International AIDS Vaccine Initiative (2023111521055128000_jiad354-B9) 2022 Aderinto (2023111521055128000_jiad354-B28) 2023; 85 Mackman (2023111521055128000_jiad354-B21) 2023 Mwesigwa (2023111521055128000_jiad354-B18) 2023 Cross (2023111521055128000_jiad354-B20) 2021; 12 Centers for Disease Control and Prevention (2023111521055128000_jiad354-B2) 2023 Mulangu (2023111521055128000_jiad354-B3) 2019; 381 Marzi (2023111521055128000_jiad354-B13) 2023; 4 Woolsey (2023111521055128000_jiad354-B15) 2023; 228 Anoshchenko (2023111521055128000_jiad354-B22) Cross (2023111521055128000_jiad354-B19) 2022; 7 Krause (2023111521055128000_jiad354-B27) 2023 Shears (2023111521055128000_jiad354-B29) 2020; 2 Cross (2023111521055128000_jiad354-B16) 2018; 17 Zhu (2023111521055128000_jiad354-B11) 2022; 10 Mire (2023111521055128000_jiad354-B8) 2017; 9 Higgs (2023111521055128000_jiad354-B5) 2021; 73 Wolf (2023111521055128000_jiad354-B6) 2021; 9 World Health Organization (2023111521055128000_jiad354-B26) 2022 Gilead Sciences (2023111521055128000_jiad354-B24) 2023 Centers for Disease Control and Prevention (2023111521055128000_jiad354-B1) 2023 US Embassy in Uganda (2023111521055128000_jiad354-B25) 2022 |
References_xml | – volume: 76 start-page: e835 year: 2023 ident: 2023111521055128000_jiad354-B4 article-title: Post-Ebola symptoms 7 years after infection: the natural history of long Ebola publication-title: Clin Infect Dis doi: 10.1093/cid/ciac732 – volume: 10 start-page: 1935 year: 2022 ident: 2023111521055128000_jiad354-B14 article-title: Single-shot ChAd3-MARV vaccine in modified formulation buffer shows 100% protection of NHPs publication-title: Vaccines (Basel) doi: 10.3390/vaccines10111935 – volume: 12 start-page: 1891 year: 2021 ident: 2023111521055128000_jiad354-B20 article-title: Combination therapy protects macaques against advanced Marburg virus disease publication-title: Nat Commun doi: 10.1038/s41467-021-22132-0 – volume: 381 start-page: 2293 year: 2019 ident: 2023111521055128000_jiad354-B3 article-title: A randomized, controlled trial of Ebola virus disease therapeutics publication-title: N Engl J Med doi: 10.1056/NEJMoa1910993 – volume: 4 start-page: e171 year: 2023 ident: 2023111521055128000_jiad354-B13 article-title: Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus–based Sudan virus vaccine: a challenge study in macaques publication-title: Lancet Microbe doi: 10.1016/S2666-5247(23)00001-0 – volume: 17 start-page: 413 year: 2018 ident: 2023111521055128000_jiad354-B16 article-title: Post-exposure treatments for Ebola and Marburg virus infections publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2017.251 – year: 2022 ident: 2023111521055128000_jiad354-B9 – volume: 7 start-page: e159090 year: 2022 ident: 2023111521055128000_jiad354-B19 article-title: Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease publication-title: JCI Insight doi: 10.1172/jci.insight.159090 – volume: 10 start-page: 1004 year: 2022 ident: 2023111521055128000_jiad354-B11 article-title: A cloned recombinant vesicular stomatitis virus–vectored Marburg vaccine, PHV01, protects guinea pigs from lethal Marburg virus disease publication-title: Vaccines (Basel) doi: 10.3390/vaccines10071004 – volume: 389 start-page: 505 year: 2017 ident: 2023111521055128000_jiad354-B17 article-title: Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) publication-title: Lancet doi: 10.1016/S0140-6736(16)32621-6 – volume: 73 start-page: 1849 year: 2021 ident: 2023111521055128000_jiad354-B5 article-title: PREVAIL IV: a randomized, double-blind, 2-phase, phase 2 trial of remdesivir vs placebo for reduction of Ebola virus RNA in the semen of male survivors publication-title: Clin Infect Dis doi: 10.1093/cid/ciab215 – ident: 2023111521055128000_jiad354-B22 – volume: 85 start-page: 2247 year: 2023 ident: 2023111521055128000_jiad354-B28 article-title: A reflection on the Marburg virus outbreak in Tanzania: the importance of preparedness and prevention in public health—a correspondence publication-title: Ann Med Surg (Lond) doi: 10.1097/MS9.0000000000000596 – start-page: 91 volume-title: NPJ Vaccines year: 2023 ident: 2023111521055128000_jiad354-B12 – volume: 2 start-page: 100038 year: 2020 ident: 2023111521055128000_jiad354-B29 article-title: The 2018/19 Ebola epidemic the Democratic Republic of the Congo (DRC): epidemiology, outbreak control, and conflict publication-title: Infect Prev Pract doi: 10.1016/j.infpip.2020.100038 – start-page: S1473-3099(23)00344-4 year: 2023 ident: 2023111521055128000_jiad354-B18 article-title: Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(23)00344-4 – volume: 9 start-page: 190 year: 2021 ident: 2023111521055128000_jiad354-B6 article-title: Development of pandemic vaccines: ERVEBO case study publication-title: Vaccines (Basel) doi: 10.3390/vaccines9030190 – year: 2023 ident: 2023111521055128000_jiad354-B27 – start-page: 1891. volume-title: J Med Chem year: 2023 ident: 2023111521055128000_jiad354-B21 – year: 2022 ident: 2023111521055128000_jiad354-B25 – volume: 25 start-page: 49 year: 2019 ident: 2023111521055128000_jiad354-B7 article-title: A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates publication-title: Cell Host Microbe doi: 10.1016/j.chom.2018.12.005 – year: 2023 ident: 2023111521055128000_jiad354-B1 – volume: 9 start-page: eaai8711 year: 2017 ident: 2023111521055128000_jiad354-B8 article-title: Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aai8711 – year: 2023 ident: 2023111521055128000_jiad354-B23 – volume: 10 start-page: 1582 year: 2022 ident: 2023111521055128000_jiad354-B10 article-title: Nonhuman primates are protected against Marburg virus disease by vaccination with a vesicular stomatitis virus vector–based vaccine prepared under conditions to allow advancement to human clinical trials publication-title: Vaccines (Basel) doi: 10.3390/vaccines10101582 – volume: 228 year: 2023 ident: 2023111521055128000_jiad354-B15 article-title: A highly attenuated panfilovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and 3 species of Ebola virus publication-title: J Infect Dis doi: 10.1093/infdis/jiad157 – year: 2022 ident: 2023111521055128000_jiad354-B26 – year: 2023 ident: 2023111521055128000_jiad354-B24 – year: 2023 ident: 2023111521055128000_jiad354-B2 |
SSID | ssj0004367 |
Score | 2.4603734 |
Snippet | Abstract
Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients... Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are... |
SourceID | proquest pubmed crossref oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | S474 |
SubjectTerms | Africa Clinical trials Disease Outbreaks - prevention & control Ebola virus Ebolavirus Filoviridae Filoviridae Infections Hemorrhagic Fever, Ebola - epidemiology Hemorrhagic Fever, Ebola - prevention & control Humans Outbreaks Vaccines |
Title | Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37596837 https://www.proquest.com/docview/3041069013 https://www.proquest.com/docview/2853948271 |
Volume | 228 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEIgXBANGYSCDkHiosiW2k6a8TWhlQutAWiv1LfJXpKItndoUif0d_MGcP-JkMMbHS9S40aX1nc_nu_vdIfSGyZKLWMmI8FhELE11xEUuI6lEIrVBDdjWCZOT7GjGPs7Tea_3vZO1tKnFnry8FlfyP1yFMeCrQcn-A2cDURiAz8BfuAKH4fpXPP7cIiWt19-2SJYukr8xM3buPIC25sJgvDhbfl2sNmtTctNEZVwynDHAwX5dng_4wMJx19aRP5hoi4buWq8tjsyXmnCJXEDRx3mCgX56AZrUi8OBwSWoEOxo-rS7nO7WI766XIQMS94Zrr1H3MLWvOvVuykINXg9B9S8Cf7YVc1wKk5y1y1pTzfaeBiBAUG76pp4MLlTuKfMNfnxmzfc5tduDK5oFgwpU7ph_GXBFU1Zuwk2gf-TT8V4dnxcTA_n01voNoHDh-mL8WHeJg4xmg2bGvTmB4dSoHTf0d_31K-YOlfgk7-cYqw1M32A7nsm4gMnUw9RT1fb6I5rTPptG92d-JSLR0h0hQwvKxyEDP8kZBjmHgchw17I3mEnYtiIGOa4I2LYi9hjNBsfTt8fRb4xRyTBfK2BJYxIQcuSMElgkdNMc00l3IlUEcGpKZLIdCxKA1vOBIuFAMs81joXCnQGfYK2qmWlnyKsmSI6EXSoFGdZHguZlzFoCwU0R2B791HUzGEhfdV60zzlrHDZE7Rwc174Oe-jt-H5C1ev5bdPvgaW_PGh3YZjhV_464LGLDEFvhPaR6_C16CWTayNVxqWXUHADB6ZErvwD3Ycp8Or6DAdZTkdPruZ-HN0r11Iu2irXm30C7CAa_HSCuQP0LK6ZQ |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Perspectives+on+Advancing+Countermeasures+for+Filovirus+Disease%3A+Report+From+a+Multisector+Meeting&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Sprecher%2C+Armand&rft.au=Cross%2C+Robert&rft.au=Marzi%2C+Andrea&rft.au=Martins%2C+Karen+A&rft.date=2023-11-15&rft.pub=Oxford+University+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=228&rft.spage=S474&rft.epage=S478&rft_id=info:doi/10.1093%2Finfdis%2Fjiad354&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |